Hormone therapy in postmenopausal women with chronic viral hepatitis C / Terapia hormonal em mulheres na pós-menopausa com hepatite crônica pelo vírus C

AUTOR(ES)
DATA DE PUBLICAÇÃO

2007

RESUMO

OBJECTIVE: To analize climacteric symptoms, liver function, hemostasis in patients with chronic viral hepatitis C, during hormone therapy. DESIGN: Patients were divided in two groups: Group TH (Case Group) - 25 patients on transdermal hormone therapy (50mcg of estradiol and 170 mcg of norethisterone/day) for 9 months, and Group NT (Control Group) - 25 hormone-untreated patients, both with climacteric symptoms. Menopause was confirmed by measuring FSH, LH and estradiol, and hepatitis C was diagnosed by serology, PCR (Polymerase Chain Reaction) and liver biopsy (histological type stages I to IV). Both groups were evaluated in the months 0, 1, 4, 7 and 9; and the climacteric symptoms measured by using Kupperman menopausal index, liver function and hemostasis by the following laboratory tests: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase, alkaline phosphatase, bilirubin, albumin, prothrombin time (PT), factor V, fibrinogen and platelets. STATISTICAL ANALYSIS: Students t test, Mann-Whitney test and two-factor analysis of variance with repeated measures were applied. After analysis of variance, multi-factor analysis of variance was applied for the statistically significant effects using contrasts or Dunnett?s test. RESULTS: The mean age of patients was 53.72 and the mean age of menopause was 47.3 years. The total mean scores for vasomotor symptoms, fatigue, palpitations and the sum of the values attributed to Kupperman menopausal index do change throughout time (p<0.05). Levels of alkaline phosphatase show alteration throughout time (p<0.05), although, other measures for liver function and hemostasis present no mean difference between the groups. CONCLUSION: There was an improvement in climacteric symptoms. No change was found in hemostasis levels or liver function. However, alkaline phosphatase levels significantly improved in Group TH starting in month 4; therefore, an increase in quality of life was observed.

ASSUNTO(S)

hormone therapy hepatite c postmenopause fígado. terapia de reposição hormonal pós-menopausa liver. estrogen estrogênio hepatitis c

ACESSO AO ARTIGO

Documentos Relacionados